Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raisedGlobeNewsWire • 04/23/24
Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPSZacks Investment Research • 04/18/24
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosisGlobeNewsWire • 04/17/24
Novartis (NVS) Presents Positive Data on Rare Kidney Disease DrugZacks Investment Research • 04/16/24
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)PRNewsWire • 04/15/24
Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win SituationSeeking Alpha • 04/11/24
Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores OptionsInvestors Business Daily • 04/11/24
Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.Barrons • 04/09/24
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world settingPRNewsWire • 04/06/24
Novartis To Seek Label Expansion of Prostate Cancer Treatment After Successful StudyInvestopedia • 04/04/24
Novartis (NVS) Declines More Than Market: Some Information for InvestorsZacks Investment Research • 04/02/24
Investors Heavily Search Novartis AG (NVS): Here is What You Need to KnowZacks Investment Research • 03/28/24
Novartis (NVS) Increases Yet Falls Behind Market: What Investors Need to KnowZacks Investment Research • 03/27/24